Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer

Jewell, Andrea; McMahon, Megan; Khabele, Dineo

doi:10.3390/cancers10090296

Cited by 24Intraperitoneal and Appendiceal MalignanciesOvarian cancer diagnosis and treatmentBRCA gene mutations in cancer

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer

Open access

Jewell, Andrea, McMahon, Megan, Khabele, Dineo·2018·Cancers

DOI 10.3390/cancers10090296PMC PMC6162496

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Heated intraperitoneal chemotherapy (HIPEC) has several potential benefits. Higher doses of chemotherapy can be used with HIPEC because the plasma-peritoneal barrier results in little absorption into the blood stream. HIPEC offers higher peritoneal penetration in comparison to an intravenous (IV) regimen and does not have the traditional normothermic intraperitoneal (IP) regimen limitation of post-operative adhesions. Hyperthermia itself has cytotoxic effects and can potentiate antineoplastic effects of chemotherapy in part by increasing the depth of tumor penetration by up to 3 mm. For the treatment of ovarian cancer, HIPEC has been evaluated in the recurrent setting with secondary cytoreduction. Recent studies, including a prospective trial, have evaluated its role in primary management of ovarian cancer. This review summarizes previous and ongoing studies regarding the use of HIPEC in the management of ovarian cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/cancers10090296

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Partial systemic restriction of intraperitoneal administration resulted in reduced toxicity and treatment-related complications.
“Furthermore, the partial systemic restriction of intraperitoneal administration resulted in reduced toxicity and treatment-related complications (44–46).”
From CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy (2020) · cites this paper as [45]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2018
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632 · see citing works
Ovarian Cancer
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,161 · see citing works
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626 · see citing works
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I. B., Trope, C. G., Amant, F. C., Kristensen, G. B., Ehlen, T., Johnson, N. P., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, Á. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,538 · see citing works
Ovarian cancer
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,853 · see citing works
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708618 · Cited by 1,445 · see citing works
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O’Toole, R. V., Williams, S. D., Young, J. A., Franklin, E. W., Clarke‐Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,226 · see citing works
Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
Markman, M. M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. Z. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,082 · see citing works
Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?
Chua, T. C., Yan, T. D., Saxena, A., et al. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a45d86 · Cited by 534 · see citing works
Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis
Chang, S., Hodeib, M., Chang, J. J., & Bristow, R. E. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.040 · Cited by 434 · see citing works
Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study
Spiliotis, J. D., Halkia, E., Lianos, E., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4157-9 · Cited by 434 · see citing works
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Helm, C. W., Richard, S. D., Pan, J., et al. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181c50cde · Cited by 302 · see citing works
Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
Tewari, D. S., Java, J., Salani, R., Armstrong, D. K., Markman, M. M., Herzog, T. J., Monk, B. J., & Chan, J. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9898 · Cited by 288 · see citing works
Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients
Bakrin, N., Béréder, J.-M., Decullier, É., et al. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.09.030 · Cited by 272 · see citing works
Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies.
Sugarbaker, P. H., Graves, T., DeBruijn, E. A., et al. (1990) · PubMed · Cited by 248 · see citing works
At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
Cohn, D. E., Kim, K. H., Resnick, K. E., O’Malley, D. M., & Straughn, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.1075 · Cited by 172 · see citing works
Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells.
Teicher, B. A., Kowal, C. D., Kennedy, K. A., et al. (1981) · PubMed · Cited by 158 · see citing works
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study
Landrum, L. M., Java, J., Mathews, C. A., Lanneau, G. S., Copeland, L. J., Armstrong, D. K., & Walker, J. L. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.04.001 · Cited by 149 · see citing works
Surgical Outcomes of Hyperthermic Intraperitoneal Chemotherapy
Jafari, M. D., Halabi, W. J., Stamos, M. J., Nguyen, V. Q., Carmichael, J. C., Mills, S., & Pigazzi, A. (2013) · JAMA Surgery · doi:10.1001/jamasurg.2013.3640 · Cited by 122 · see citing works
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Vergote, I. B., Chiva, L., & du Bois, A. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1802033 · Cited by 117 · see citing works
Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery
Bae, J. H., Lee, J. M., Ryu, K. S., et al. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.03.019 · Cited by 108 · see citing works
Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case–control study on survival in patients with two year follow-up
Fagotti, A., Costantini, B., Petrillo, M., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.09.020 · Cited by 107 · see citing works
HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum‐based chemotherapy in patients with platinum‐sensitive recurrent epithelial ovarian cancer
Zivanovic, O., Abramian, A., Kullmann, M., Fuhrmann, C., Coch, C., Hoeller, T., Ruehs, H., Keyver-Paik, M., Rudlowski, C., Weber, S. U., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29011 · Cited by 96 · see citing works
Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases
Giorgio, A. D., Iaco, P. D., Simone, M. D., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5686-1 · Cited by 95 · see citing works
Secondary Cytoreductive Surgery in Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Panici, P. B., Vivo, A. D., Bellati, F., et al. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9273-8 · Cited by 88 · see citing works
Treatment of Microscopic Disease with Hyperthermic Intraoperative Intraperitoneal Chemotherapy After Complete Cytoreduction Improves Disease-Free Survival in Patients with Stage IIIC/IV Ovarian Cancer
Cascales-Campos, P. A., Gil, J., Gil, E., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3599-4 · Cited by 88 · see citing works
A Theoretical Model for Intraperitoneal Delivery of Cisplatin and the Effect of Hyperthermia on Drug Penetration Distance
El-Kareh, A. W., & Secomb, T. W. (2004) · Neoplasia · doi:10.1593/neo.03205 · Cited by 85 · see citing works
Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry
Sun, X., Li, X.-F., Russell, J., Xing, L., Urano, M., Li, G. C., Humm, J. L., & Ling, C. C. (2008) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.05.015 · Cited by 68 · see citing works
Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Petrillo, M., Iaco, P. D., Cianci, S., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5050-x · Cited by 66 · see citing works
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer
Provencher, D. M., Gallagher, C., Parulekar, W. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx754 · Cited by 65 · see citing works
The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies
Katz, M. H. G., & Barone, R. M. (2003) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(03)00034-6 · Cited by 64 · see citing works
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., et al. (2018) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000532155.55081.57 · Cited by 55 · see citing works
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: Upfront therapy, at first recurrence, or later?
Bayón, L. G., Steiner, M. Á., Jiménez, W. V., et al. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.06.022 · Cited by 50 · see citing works
Surgery in recurrent epithelial ovarian cancer: Benefits on Survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction
Tian, W., Jiang, R., Cheng, X., et al. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21491 · Cited by 48 · see citing works
Cost Effectiveness of Intraperitoneal Compared With Intravenous Chemotherapy for Women With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
Havrilesky, L. J., Secord, A. A., Darcy, K. M., Armstrong, D. K., & Kulasingam, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1961 · Cited by 47 · see citing works
The Role of Hyperthermic Intraperitoneal Chemotherapy Using Paclitaxel in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer Patients with Microscopic Residual Disease after Cytoreduction
Cascales-Campos, P. A., Gil, J., Feliciangeli, E., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4049-z · Cited by 46 · see citing works
A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology Study
Walker, J. L., Brady, M. F., DiSilvestro, P., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.535 · Cited by 42 · see citing works
Cytoreductive surgery with a hyperthermic intraperitoneal chemotherapy program: Safe after 40 cases, but only controlled after 140 cases
Voron, T., Eveno, C., Jouvin, I., et al. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.09.005 · Cited by 39 · see citing works
Bevacizumab in Treatment of High-Risk Ovarian Cancer—A Cost-Effectiveness Analysis
Chan, J. K., Herzog, T. J., Hu, L., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0322 · Cited by 38 · see citing works
Heat-Induced Modifications in the Association of Specific Proteins with the Nuclear Matrix
Vanderwaal, R. P., Thampy, G., Wright, W. D., et al. (1996) · Radiation Research · doi:10.2307/3579366 · Cited by 27 · see citing works
HIPEC in patients with primary advanced ovarian cancer: Is there a role? A systematic review of short- and long-term outcomes
Kireeva, G. S., Гафтон, Г. И., Guseynov, K. D., et al. (2018) · Surgical Oncology · doi:10.1016/j.suronc.2018.05.006 · Cited by 23 · see citing works
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study
Dizon, D. S., Sill, M. W., Gould, N., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.07.016 · Cited by 17 · see citing works
Hsp90-containing multiprotein complexes in the eukaryotic microbe Achlya
Brunt, S. A., Perdew, G. H., Toft, D. O., & Silver, J. C. (1998) · Cell Stress and Chaperones · doi:10.1379/1466-1268(1998)003 · Cited by 14 · see citing works
Surgical Outcomes of Hyperthermic Intraperitoneal Chemotherapy: Analysis of the American College of Surgeons National Surgical Quality Improvement Program
Jafari, M. D., Halabi, W. J., Stamos, M. J., et al. (2014) · eScholarship (California Digital Library) · Cited by 13 · see citing works

Flagged first, then by citations

Sorted by citations

CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy
Rosenblum, D., Gutkin, A., Kedmi, R., Ramishetti, S., Veiga, N., Jacobi, A. M., Schubert, M. S., Friedmann-Morvinski, D., Cohen, Z. R., Behlke, M. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc9450 · Cited by 614 · see citing works

02 / Postoperative outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
Yasuma, F. (2018) · doi:10.26226/morressier.5aeb0ac507b0d6001a79a011
Surgical morbidity and mortality in patients undergoing extended cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
Zambonin, D., Martino, C. D., Scaringi, S., et al. (2012) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2012.07.068
Morbidity, mortality and long-term survival in patients undergoing extended cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
Zambonin, D., Martino, C. D., Scaringi, S., et al. (2012) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2012.07.069
117. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of peritoneal surface malignancies in the elderly
Dux, J., Rayman, S., Zendel, A., et al. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.06.123
Cytoreductive Reductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Ovarian Cancer
Tan, G. H. C. (2016) · doi:10.26226/morressier.5770e29cd462b80290b4be7e

Authors: Jewell, A., McMahon, M., & Khabele, D.
Affiliations: University of Kansas Medical Center (US)
Corresponding author: Jewell, Andrea
ORCID: Jewell, Andrea
Khabele, Dineo
Venue: Cancers
Publisher: MDPI AG
Published: 2018-09-01
Volume: 10
Issue: 9
Pages: 296
ISSN: 2072-6694 (ISSN-L)
DOI: 10.3390/cancers10090296
PMC: PMC6162496
OpenAlex: W2891510959
Cited by: 24
References: 44
Citations by year: 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 9 · 2019: 5 · 2018: 1
FWCI: 1.00
Type: journal article
Language: en
Open access: gold
dx.doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Cancers (publishedVersion, cc-by)
Preprints.org (acceptedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, other-oa)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: hyperthermic intraperitoneal chemotherapy, advanced ovarian cancer, recurrent ovarian cancer, secondary cytoreductive surgery, primary cytoreduction, hyperthermia, peritoneal penetration, postoperative adhesions, chemotherapy dosing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks